Attgeno AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.attgeno.com
Clinical Trials
6
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
Phase 2
Recruiting
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 12
- Registration Number
- NCT05699486
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Anaesthesiology and Intensive Care, Gothenburg, Sweden
🇸🇪Örebro University Hospital, Vascular and Thoracic Department (Kärl-Thoraxkliniken), Örebro, Sweden
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
Phase 1
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 38
- Registration Number
- NCT04891354
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
Phase 1
Withdrawn
- Conditions
- Pulmonary HypertensionCOVID-19
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Attgeno AB
- Registration Number
- NCT04885491
- Locations
- 🇸🇪
Danderyd Hospital, Danderyd, Sweden
🇸🇪Örebro University Hospital, Örebro, Sweden
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
Completed
- Conditions
- COVIDHypertension, PulmonaryRight Ventricular Overload
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 67
- Registration Number
- NCT04459364
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
News
No news found